The most important idea: set and setting
The single best-supported principle in this entire field is that the molecule is only half the story. Set (your mindset, intention, and emotional state) and setting (your physical and social surroundings) are not soft add-ons — they are primary determinants of whether an experience heals or harms.
The traditions understood this long before science did. The Mazatec velada, the Amazonian ayahuasca ceremony, and the Bwiti iboga initiation are each a whole container — music, guidance, safety, meaning — not just a dose. A recent analysis of clinical data even found that the therapeutic relationship works indirectly: a strong, trusting container doesn't heal on its own — it makes a meaningful experience possible, and that experience is what carries the benefit (Goodwin et al., 2026). The container is not optional. It is the mechanism.
Dangerous interactions — the ones that actually matter
Ayahuasca + antidepressants (SSRIs/SNRIs)
SeriousAyahuasca works precisely because it contains an MAO inhibitor (the beta-carbolines that let DMT survive digestion). Combining an MAO inhibitor with common antidepressants (SSRIs and SNRIs) risks serotonin syndrome, a potentially life-threatening reaction. This is the clearest, best-established danger in the whole family — and the pharmacological basis for the warnings every reputable ceremony gives.
Iboga / ibogaine — the heart
SeriousIbogaine can disturb the heart's rhythm (it prolongs the QT interval), and this cardiac risk is real and has caused deaths. Serious clinical programs use it only with cardiac screening and monitoring — the 2024 Nature Medicine veterans study paired it with magnesium specifically to protect the heart. This is never a casual, unsupervised substance.
A vulnerability to psychosis
Screen for itFor a person with a personal or strong family history of psychosis or bipolar disorder, classic psychedelics can be genuinely risky. Reputable research screens carefully for exactly this. The physical toxicity of psilocybin is very low — but "low physical risk" is not the same as "no risk," and the real hazards here are psychological.
Dose: the quiet problem
You cannot dose safely what you cannot measure. Mushroom potency varies as much as fortyfold between samples — the name on the jar is a weak predictor of strength. The 2026 evidence is also clear on one point that cuts against a popular trend: for depression, a standard, full dose works, while microdosing has not shown benefit over placebo in controlled trials. And a practical warning from the chemistry: because of the possible "entourage" effect, a whole mushroom should never be swapped one-for-one for an "equivalent" dose of pure psilocybin — it may hit harder.
The part everyone skips: integration
If there is a single insight this organization wants to leave you with, it is this. The evidence increasingly suggests that these substances open a temporary window of neuroplasticity — a period when the brain is unusually ready to form new patterns. Which means the experience is not the finish line. What you do afterward — the reflection, the journaling, the changes in how you live, ideally with support — may matter as much as the experience itself. An insight that is never integrated fades. Integration is where a moment becomes a change.